Cargando…
A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.
In a non-randomised study in six centres in the UK, 24 patients with previously untreated small-cell lung cancer of limited extent were treated with a regimen of alternating chemotherapy and radiotherapy to assess response, toxicity, and the feasibility of applying such a regimen on a multicentre ba...
Autores principales: | Bleehen, N. M., Girling, D. J., Gregor, A., Leonard, R. C., Machin, D., McKenzie, C. G., Morgan, D. A., Smyth, J. F., Spittle, M. F., Stephens, R. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977679/ https://www.ncbi.nlm.nih.gov/pubmed/1654988 |
Ejemplares similares
-
Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1994) -
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993) -
Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party.
por: Fayers, P. M., et al.
Publicado: (1991) -
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
por: Bleehen, N. M., et al.
Publicado: (1993) -
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
por: Stephens, R. J., et al.
Publicado: (1996)